TARO-TESTOSTERONE CYPIONATE INJECTION SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

TESTOSTERONE CYPIONATE

متاح من:

TARO PHARMACEUTICALS INC

ATC رمز:

G03BA03

INN (الاسم الدولي):

TESTOSTERONE

جرعة:

100MG

الشكل الصيدلاني:

SOLUTION

تركيب:

TESTOSTERONE CYPIONATE 100MG

طريقة التعاطي:

INTRAMUSCULAR

الوحدات في الحزمة:

15G/50G

نوع الوصفة الطبية :

Schedule G (CDSA IV)

المجال العلاجي:

ANDROGENS

ملخص المنتج:

Active ingredient group (AIG) number: 0106401001; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2020-01-29

خصائص المنتج

PRODUCT MONOGRAPH TARO-TESTOSTERONE CYPIONATE INJECTION
Testosterone Cypionate Injection
100 mg / mL sterile solution
Taro Standard
Androgens
Taro Pharmaceutical Inc.
130 East Drive
Brampton, ON
L6T 1C1 Canada
Date of Revision:
May 26, 2022
Submission Control No: 263625
_Page 1 of 20_
_Page 2 of 20_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL
USE..........................................................................3
CONTRAINDICATIONS..............................................................................................4
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................4
WARNINGS AND PRECAUTIONS
.............................................................................4
ADVERSE REACTIONS
..............................................................................................8
DRUG INTERACTIONS
..............................................................................................9
DOSAGE AND ADMINISTRATION
.........................................................................
10
OVERDOSAGE
.........................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 12
STORAGE AND STABILITY
....................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
................................................................... 14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 14
PART II: SCIENTIFIC INFORMATION
.........................................................................
15
PHARMACEUTICAL INFORMATION
.....................................................................
15
CLINICAL TRIALS
.............................................................